New diabetes shot GZR18 takes on semaglutide in major trial
NCT ID NCT06778967
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 study tests a new injectable drug called GZR18 in about 1,100 Chinese adults with type 2 diabetes whose blood sugar is not well controlled by metformin or other oral medications. Participants receive either GZR18 or the approved drug semaglutide to compare how well each lowers blood sugar and affects weight. The goal is to see if GZR18 is a safe and effective new treatment option.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- GZR18 injection (a drug similar to semaglutide, given as a shot under the skin)
- What this could lead to
- If it works, this could offer a new once-weekly injection option to help people with type 2 diabetes lower blood sugar and possibly lose weight.
- What could go wrong
- This is a phase 3 trial, but it only includes Chinese participants, so results may not apply to other groups. GZR18 is new and may cause side effects like nausea or vomiting, common with this class of drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 1,100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2025
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * T2DM is diagnosed for at least 12 weeks according to the diagnostic criteria of diabetes mellitus issued by the World Health Organization (WHO) in 1999 and the supplementary diagnostic criteria of WHO in 2011 (HbA1c diagnosis is recommended). * Antidiabetic drugs that meet any of the following within 8 weeks before screening: * A stable dose of metformin hydrochloride monotherapy at a dose of ≥ 1500 mg/day or the maximum tolerated dose ; * A stable dose of metformin (≥ 1500 mg/day or the maximum tolerated dose ) in combination with SGLT2 inhibitors; * A stable dose of metformin (≥1500 mg/day or a maximum tolerated dose \< 1500 but ≥ 1000 mg/day) in combination with a stable daily dose of sulfonylureas. * HbA1c ≥ 7.5% and ≤ 11% at screening (central laboratory). * BG \< 15 mmol/L at screening (central laboratory). Exclusion Criteria: * Type 1 diabetes mellitus or special type of diabetes mellitus. * Diabetic ketoacidosis, diabetic lactic acidosis or hyperosmolar state within 6 months before screening, or diabetic ketosis at screening/before randomization. * Severe chronic complications of diabetes (such as proliferative retinopathy or maculopathy, diabetic painful neuropathy, intermittent claudication, or diabetic foot) at screening or before randomization. * History of acute or chronic pancreatitis and pancreatic injury before screening. * History or relevant family history of medullary thyroid cancer, multiple endocrine neoplasia (MEN) 2A or 2B before screening. * Any laboratory test indicator meeting the following criteria at screening or before randomization: * Calcitonin level ≥ 50 ng/L (pg/mL) at screening. * ALT ≥ 3.0 × upper limit of normal (ULN) or AST ≥ 3.0 × ULN or total bilirubin ≥ 2.0 × ULN. * Estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2, calculated using CKD-EPI equation (see Appendix 3). * Fasting triglyceride (TG) ≥ 5.7 mmol/L or 500 mg/dL. * Blood amylase or lipase \> 1.5 × ULN. * Hemoglobin ≤ 100 g/L for women and ≤ 110 g/L for men.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Type 2 diabetes mellitus (T2DM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University General Hospital
Tianjin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Four pills, one goal: can a new combo tame type 2 diabetes?
- Can banding the gut tame type 2 diabetes?
- Can QR codes and videos teach better foot care?
- Can a new injection help tackle obesity? a trial puts MWN105 to the test
- Can when you eat change how a diabetes drug works?
- Can a new daily pill outperform semaglutide for diabetes?